Comparison of the Efficacy of Topical Luliconazole 2% Cream vs Topical Ketoconazole 1% Cream in the Treatment of Pityriasis Versicolor.
Starting soon · Phase 4
Conditions studied: Pityriasis Versicolor
In brief
Pityriasis versicolor is a common superficial fungal infection caused by Malassezia species, characterized by hypo- or hyper-pigmented scaly patches on the skin. Topical antifungal agents are the mainstay of treatment. Ketoconazole has been widely used; however, newer agents such as luliconazole may offer improved efficacy and shorter treatment duration. This randomized controlled study aims to compare the efficacy and safety of topical luliconazole versus topical ketoconazole in patients with pityriasis versicolor. Treatment response will be assessed clinically and mycologically to determine comparative outcomes.
Key facts
- Study ID
- NCT07333170
- Run by
- PAEC General Hospital, Islamabad
- People needed
- 86
- Starts
- 2026-02-01
- Expected to finish
- 2026-11-01
- Last updated by the study team
- 2026-01-12
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- All patients diagnosed with pityriasis versicolor.
You may not qualify if…
- Immunocompromised patients
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.